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Diastolic function is a strong predictor of mortality in patients with chronic kidney
disease
Abstract
Background: Cardiovascular disease is a major cause of death in patients with stage 4-5 Chronic Kidney
disease (CKD, eGFR < 30). There are only limited data on the risk factors predicting these complications in
CKD patients. Our aim was to determine the role of clinical and echocardiographic parameters in
predicting mortality and cardiovascular complications in CKD patients. Methods. We conducted a
prospective observational cohort study of 153 CKD patients between 2007 and 2009. All patients
underwent echocardiography at baseline and were followed for a mean of 2.6 years using regular clinic
visits and review of files and hospital presentations to record the incidence of cardiovascular events and
death. Results: Of 153 patients enrolled, 57 (37%) were on dialysis and 45 (78%) of these patients were on
haemodialysis. An enlarged LV was present in 32% of patients and in 22% the LVEF was below 55%. LV
mass index was increased in 75% of patients. Some degree of diastolic dysfunction was present in 85%
of patients and 35% had grade 2 or higher diastolic dysfunction. During follow up 41 patients (27%) died,
15 (39%) from cardiovascular causes. Mortality was 24.0% in the non-dialysis patients versus 31.6% in
patients on dialysis (p=ns). On multivariate analysis age >75 years, previous history of MI, diastolic
dysfunction and detectable serum troponin T were significant independent predictor of mortality (P <
0.01). Conclusion: Patients with stage 4-5 CKD had a mortality rate of 27% over a mean follow up of 2.6
years. Age >75 years, history of MI, diastolic dysfunction and troponin T were independent predictors of
mortality.
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Diastolic function is a strong predictor of
mortality in patients with chronic kidney disease
Ahmad Farshid1*, Rajeev Pathak1, Bruce Shadbolt2,4, Leonard Arnolda1,4 and Girish Talaulikar3,4

Abstract
Background: Cardiovascular disease is a major cause of death in patients with stage 4–5 Chronic Kidney disease
(CKD, eGFR < 30). There are only limited data on the risk factors predicting these complications in CKD patients. Our
aim was to determine the role of clinical and echocardiographic parameters in predicting mortality and
cardiovascular complications in CKD patients.
Methods: We conducted a prospective observational cohort study of 153 CKD patients between 2007 and 2009. All
patients underwent echocardiography at baseline and were followed for a mean of 2.6 years using regular clinic
visits and review of files and hospital presentations to record the incidence of cardiovascular events and death.
Results: Of 153 patients enrolled, 57 (37%) were on dialysis and 45 (78%) of these patients were on haemodialysis. An
enlarged LV was present in 32% of patients and in 22% the LVEF was below 55%. LV mass index was increased in 75%
of patients. Some degree of diastolic dysfunction was present in 85% of patients and 35% had grade 2 or higher
diastolic dysfunction. During follow up 41 patients (27%) died, 15 (39%) from cardiovascular causes. Mortality was 24.0%
in the non-dialysis patients versus 31.6% in patients on dialysis (p=ns). On multivariate analysis age >75 years, previous
history of MI, diastolic dysfunction and detectable serum troponin T were significant independent predictor of mortality
(P < 0.01).
Conclusion: Patients with stage 4–5 CKD had a mortality rate of 27% over a mean follow up of 2.6 years.
Age >75 years, history of MI, diastolic dysfunction and troponin T were independent predictors of mortality.
Keywords: Chronic kidney disease, Echocardiography, Diastolic function, Cardiovascular disease, Troponin T

Background
Cardiovascular disease is the major cause of death in patients with advanced chronic kidney disease (CKD stages
4–5, eGFR <30 mL/min/1.73 m2), accounting for about
40% of deaths in international registries [1]. The risk of cardiovascular mortality is more than 10 times higher in this
population compared with an age, sex, and race matched
population [2]. Data on cardiovascular risk factors from
the general population cannot simply be extrapolated to
CKD patients as they are subject not only to traditional risk
factors, but also to CKD-related risk factors such as inflammation, increased calcium and phosphorus products,
uremic toxins, anemia, and fluid overload [3,4]. Additionally, CKD patients show a very high prevalence of vascular
and valvular calcification which have been shown to be

associated with increased arterial stiffness and adverse outcomes [5,6].
Echocardiography provides a non-invasive assessment of
cardiac structures and function. There is limited data on
echocardiographic parameters predicting cardiovascular
complications in patients with advanced CKD, including
those who have not commenced dialysis [7-9]. Our aim
was to assess the role of echocardiographic and clinical parameters and cardiac biomarkers in predicting death and
cardiovascular complications in patients with advanced
CKD and to compare non-dialysis patients with those on
dialysis.

Methods
Study subjects

* Correspondence: afarshid@tpg.com.au
1
Cardiology Unit, The Canberra Hospital, PO Box 11, Woden, ACT 2605,
Australia
Full list of author information is available at the end of the article

We conducted a 4 year prospective observational study,
enrolling 153 consecutive patients between May 2007
and May 2009. The setting of the study was the Renal
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Outpatient Clinic of a Public tertiary referral hospital with
approximately 400 outpatients with GFR <30 ml/min and
200 dialysis patients. Consecutive adult patients with stage
4–5 CKD (eGRF < 30 mL/min/1.73 m2 using the modified
MDRD equation) attending the Clinic were screened and
invited to take part, including patients who were already
on dialysis. Patients were excluded if they were unable or
unwilling to return for regular follow up or were at high
risk of death due to any cause within 6 months of enrolment. The investigation conforms with the principles outlined in the Declaration of Helsinki and was approved by
the Australian Capital Territory Human Research Ethics
Committee. All subjects gave informed written consent to
take part in the study. Demographic and clinical characteristics were recorded and patients underwent echocardiography and blood tests (full blood count, electrolytes, urea
and creatinine, calcium, phosphate and serum troponin T)
at the time of entry into the study.

Troponin T analysis

Analysis was carried out on the Roche Elecsys1010
(Roche Diagnostics Australia, Sydney, Australia). The
limit of detection for this assay is 0.01 mcg/L with assay
coefficients of variation (CV) being 6.0% at 0.11 mg/L
and 2.5% at 2.5 mg/L.

Echocardiography

2D and Doppler echocardiography was carried out on all
patients lying in the left decubitus position at baseline. All
studies were performed by a single experienced sonographer blinded to the clinical details of patients using a
Philips iE33 echocardiographic system with a S5-1 probe.
For patients on dialysis all studies were performed within
24 hour after dialysis. All echocardiographic data were
measured according to the guidelines of the American Society of Echocardiography (ASE) [10]. LV mass was calculated using the ASE-recommended formula for estimation
of LV mass from linear dimensions and was indexed to
body mass. The left ventricular ejection fraction (LVEF)
was measured in the apical views using Simpson’s
method. Diastolic function was assessed using several
parameters including the pattern of mitral inflow and
the ratio of peak early (E) filling velocity to late diastolic filing (A) velocity (E/A ratio), deceleration time
of early filling velocity (DT), and the isovolumic relaxation time (IVRT). PW Tissue Doppler Imaging was
performed in the apical views to acquire mitral annular
velocities. The ratio of early mitral inflow velocity to
Tissue Doppler velocity e’ (E/e’) was used for the
estimation of LV filling pressures. Diastolic function
was classified into grades I-IV according to the ASE
guidelines [11].
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Endpoints and Follow up

The primary endpoint was death from any cause. The secondary endpoint was the incidence of Major Adverse Cardiovascular Events (MACE) including death, myocardial
infarction (MI), unstable angina, stroke and heart failure.
MI was defined according to ESC guidelines 2007 as a rise
and fall of troponin-I with at least one value above the 99th
percentile of the upper reference limit together with evidence of myocardial ischaemia [12]. Unstable angina was
defined as cardiac ischaemic pain associated with ≥ 1 mm
ST segment depression on ECG resulting in hospitalisation.
Cardiac failure was defined according to the ESC definition
of heart failure (2005) as presentation to a health care facility with symptoms of heart failure (typically breathlessness
or fatigue), or ankle swelling and objective evidence of cardiac dysfunction at rest [13]. Cerebrovascular accident was
defined as in the TREAT Study as a focal neurological deficit resulting from a vascular cause involving the central
nervous system with a sudden onset and lasting longer
than 24 hours [14]. Follow up of the patients was by clinic
visits, phone calls and review of the clinical notes every six
months.
Statistical analysis

In addition to descriptive analyses, Cox proportional hazards models were used to test the univariate and multivariate associations between survival and the subjects’ risk
factors. In the multivariate analysis, after adjusting for age
and gender as well as diabetes and other risk factors
(hypertension, smoking, hyperlipidaemia), a likelihood ratio
method for factor inclusion was employed. Hazard ratios
and the associated 95% confidence intervals and p values
are shown in the results. SPSS version 19.0 was used to
conduct the analyses and a two sided p value of <0.05 was
considered significant.

Results
Baseline characteristics for 153 enrolled patients are shown
in Table 1. Patients on dialysis made up 38% of the study
population, 78% of whom were on haemodialysis. A history
of MI was present in 20% of patients and 46% were diabetic. An enlarged left ventricle was present in 32% and in
22% the LVEF was below 55%. LV mass index was increased in 75% of patients. Some degree of diastolic dysfunction was present in 85% of patients and 35% had grade
2 or higher diastolic dysfunction. Diastolic function could
not be assessed in 16 patients (10%), mostly due to presence of atrial fibrillation. Follow up was for a mean of
2.6 years (median 2.89 years) and was available in all but 1
patient who moved to another state.
Clinical, biochemical and echocardiographic results as
well as incidence of adverse events for dialysis and nondialysis patients are shown in Table 2. There was a higher
incidence of LV dysfunction and troponin T elevation in
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Table 1 Baseline characteristics of patients
Number (%)
Mean age (year)

65.6 ± 14.0

Male gender

88 (57.5%)

Medical history
Hypertension

127 (85%)

Diabetes

69 (46%)

Oral hypoglycaemics

25 (17%)

Insulin

34 (23%)

Heart failure

20 (13%)

Stroke

23 (15%)

Hyperlipidaemia

90 (60%)

Current smoker

15 (10%)

Atrial fibrillation

10 (6.5%)

AMI

30 (20%)

PCI

25 (16%)

CABG

17 (11%)

Patients on dialysis

56 (37%)

Haemodialysis

45 (29%)

Peritoneal dialysis

13 (8%)

Aetiology of kidney disease:
Diabetes

48 (31%)

Glomerulonephritis

39 (25%)

Vascular

13 (8%)

Hypertension

10 (7%)

Vesicoureteric reflux

9 (6%)

Congenital

6 (4%)

Other

28 (18%)

Medications

Table 2 Clinical and echocardiographic characteristics in
dialysis and non-dialysis patients
Nondialysis

Dialysis

P
value

96

57

NA

Mean age

69.7 ± 11.7

58.7 ± 15.0

<0.0001

Female sex

40 (42%)

25 (44%)

NS

Diabetes

45 (47%)

24 (42%)

NS

History of MI

18 (19%)

12 (21%)

NS

123.8 ± 15.4

117.0 ± 12.3

0.0058

White cell count

7.38 ± 2.0

7.57 ± 2.13

NS

Platelet count

238 ± 63

232 ± 88

NS

Sodium

139.9 ± 2.6

137.4±

<0.0001

Potassium

4.46 ± 0.59

4.41±

NS

Urea (mmol/L)

18.9 ± 6.9

19.2 ± 6.7

NS

Creatinine (umol/L)

255 ± 88

646 ± 229

<0.0001

Number

Blood indices:
Haemoglobin (g/L)

eGFR (mL/min/1.73 m2)

22.3 ± 7.4

8.3 ± 4.9

<0.0001

Calcium (mmol/L)

2.40 ± 0.12

2.38 ± 0.17

NS

Phosphate (mmol/L)

1.31 ± 0.29

1.84 ± 0.55

<0.0001

Parathyroid hormane

23.6 ± 29.1

51.4 ± 48.6

<0.0001

Troponin T detected

36 (38%)

44 (79%)

<0.001

Echocardiographic results
LV diameter (mm)

49.5 ± 5.9

49.8 ± 6.2

NS

LV ejection fraction

62.1 ± 10.0

61.0 ± 14.0

NS

LV mass index

121.7 ± 35.4

126.8 ± 33.6

NS

Left atrial area (cm2)

22.1 ± 6.0

21.6 ± 4.9

NS

Aortic peak velocity (m/s)

1.50 ± 0.42

1.57 ± 0.47

NS

8 (8.3%)

6 (10.5%)

NS

2.53 ± 0.44

2.59 ± 0.45

NS

Mitral regurgitation
(moderate or severe)

ACEI/ARB

86 (56%)

Diuretic

58 (38%)

Beta blocker

64 (42%)

Diastolic grade:

Statin

92 (60%)

Grade 0

14 (16.3%)

7 (13.7%)

NS

Calcium antagonist

60 (39%)

Grade 1

48 (55.8%)

24 (47.1%)

NS

Aspirin

42 (27%)

Grade 2

16 (18.6%)

15 (29.4%)

NS

EPO

65 (42%)

Grade 3-4

8 (9.3%)

5 (9.8%)

NS

Indeterminate grade

9 (9.5%)

7 (12.1%)

NS

Death

23 (24.0%)

18 (31.6%)

NS

MACE

27 (28.1%)

24 (42.1%)

0.06

dialysis patients but there were no other significant differences between the two groups. Mortality was 24% in the
non-dialysis patients versus 31.6% in patients on dialysis
(p=ns).
Adverse events during follow up for the entire cohort are
shown in Table 3. During this time 41 patients (27%) died,
15 (39%) of whom died from cardiovascular causes. Survival analysis was performed to determine univariate clinical and echocardiographic factors predictive of death and
adverse cardiovascular events (Table 4). Clinical predictors
of death included age >75 years and a history of MI.

Tricuspid regurgitation
peak velocity (m/s)

Clinical outcomes

LVEF, Left ventricular ejection fraction; LVMI, Left ventricular mass index; MACE,
Major adverse cardiovascular events, diastolic function was classified into
grades 1–4 according to the ASE guidelines.

Univariate echocardiographic predictors of mortality included enlargement of left ventricle and the left atrium,
low LVEF, increased LV mass index and grade 2 or higher
diastolic dysfunction. On multivariate analysis (Cox
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Table 3 Incidence of adverse events during 2.6 years
follow up
Adverse events

Number (%)

Acute MI

14 (9.1%)

Unstable angina

13 (8.5%)

Cardiac failure

10 (6.5%)

Cerebrovascular accident

6 (3.9%)

Percutaneous coronary intervention

7 (4.6%)

Death from any cause

41 (27%)

Cause of death:
Sepsis

9 (22%)

Renal failure

8 (20%)

Cancer

7 (17%)

Acute MI

4 (10%)

Sudden death

5 (12%)

Cardiac failure

3 (7%)

Cerebrovascular accident

4 (10%)

All cardiovascular death

16 (39%)

Accident

1 (2%)

Regression) age >75 and previous history of MI remained
significant. With regard to echo parameters, diastolic dysfunction remained as a significant predictor of mortality,
whereas LV mass index and LVEF were no longer significant. Detection of Troponin T in the serum was also an
independent predictor of mortality during follow up.

Discussion
Cardiovascular disease is the leading cause of death in
patients with advanced CKD [2]. Our study has shown
that patients with advanced CKD had a mortality rate of
27% (39% from cardiovascular causes) over a mean follow up of 2.6 years. The overall mortality rate was
higher than in the placebo group in the SHARP Trial
which enrolled patients with moderate to severe CKD
with one third on dialysis (24.1% after 4.9 years) [15].
This is possibly explained by the higher age of our cohort (66 years v 62 years in SHARP) and the inclusion
of more patients on dialysis. The UK Renal Registry of

5447 patients starting dialysis (mean age 64) documented a mortality rate of 29.7% after 3 years [16]. The
mortality rate in our non-dialysis group, a cohort which
has not been studied extensively in other studies, was
surprisingly high at 24%. TREAT which studied diabetic
patients with a GFR of 20–60 mL/min/1.73 m2 reported
a mortality of 20% after a median 2.4 years follow up
[17]. The CRIC study which enrolled 3939 patients with
stage 2–4 CKD recently reported an overall mortality
rate of 9.5% and a combined incidence of MI, CVA and
peripheral vascular disease of 8.4% [18]. Mean eGFR in
the CRIC study patients was 44.8 ml/min/1.73 m2 compared with 22.3 ml/min/1.73 m2 in our non-dialysis
(stage 4) patients.
The pathophysiology of cardiac disease in CKD is related
to the interaction of multiple factors including hypertension, chronic volume overload, anaemia, presence of an AV
fistula in patients on dialysis, as well as metabolic factors
such as acidosis, hypoxia, hypocalcaemia and high levels of
parathyroid hormone [3,4]. Morphological changes in the
heart include LVH, advanced coronary atherosclerosis,
microvascular disease and diffuse interstitial myocardial
fibrosis [19,20]. These abnormalities are common in
CKD patients and have been shown in to be predictive
of mortality [21,22].
Assessment of diastolic function by echocardiography
has shown a high incidence of abnormalities in dialysis and
non-dialysis CKD patients [23,24]. Some investigators have
found abnormalities in tissue Doppler velocity in virtually
all patients with CKD, suggesting a degree of subclinical
myocardial disease in all such patients [25]. In the CRIC
study (stage 2–4 CKD) diastolic function was abnormal in
71% of patients [26]. In our cohort some degree of diastolic dysfunction was present in 85% of patients and 35%
had grade 2 or higher diastolic dysfunction, which was a
powerful independent predictor of mortality. Patients with
abnormal diastolic function have been found to have increased integrated backscatter which is a measure of collagen content of myocardial tissue [27]. We used E/é as part
of our grading of diastolic function and this has been
shown to reflect LV filling pressure and has been associated with mortality in CKD patients [24].

Table 4 Univariate and multivariate predictors of mortality in advanced CKD patients
Factor

Univariate P value

Multivariate P Value

Hazard ratio

Lower 95% CI

Upper 95% CI

Age >75

0.0005

0.002

3.21

1.53

6.74

History of MI

<0.0001

0.007

2.72

1.32

5.64

LVEF < 55%

0.02

NS

NA

NA

NA

High LVMI

0.03

NS

NA

NA

NA

Diastolic grade > 1

0.0005

0.001

3.42

1.66

7.08

Elevated troponin T

<0.0001

0.005

3.70

1.50

9.18

Independent variables entered in the Cox Regression model: age, sex, diabetes, history of MI, LVEF, LVMI, Diastolic grade >1, Troponin T. CI, confidence interval;
LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index.
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We detected troponin T in 38% of non-dialysis and 79%
of dialysis patients. Troponin T was detected in 45% of
diabetic CKD patients in TREAT and was an independent
predictor of adverse outcomes in this and other studies
[17,28]. The precise mechanism for increased Troponin T
concentrations in advanced CKD patients is not clear.
Acute myocardial ischaemia may be a factor in a minority
of patients as suggested by an MRI study in ESRD patients
with raised troponins [29]. None of our patients had clinical evidence of myocardial infarction at the time of their
blood test. A post-mortem study of patients with raised
troponin T which included 6 haemodialysis patients found
histologic evidence of myocardial infarction in some patients but also other cellular pathologies in virtually all
subjects including degenerative changes associated with
heart failure, inflammation, fibrosis, endocarditis, sepsis,
amyloid deposition, and infiltration by tumour [30]. The
concept of myocyte damage in these patients is supported
by findings of a higher incidence of LV dilatation, increased LV mass, impaired systolic function and raised LV
filling pressures [24]. The situation is made more complex
by availability of high sensitivity assays which detect troponin T in virtually all advanced CKD patients [31]. In the
CRIC study high sensitivity Troponin T was detected in
84% of stage 2–4 CKD patients and was associated with
LVH and systolic dysfunction [32].
Detection of significant diastolic dysfunction and elevated troponin T can be early markers of myocardial
disease and increased risk in advanced CKD. However,
the optimal management of these patients is not well
defined. Therapeutic modalities that have been successfully used include aggressive lipid lowering [15], treatment for hypertension and anaemia [33], increased
frequency of dialysis [34], implantable defibrillator insertion [35], coronary revascularisation [36], multiple
risk factor intervention [37] and renal transplantation.
The application of these therapies should be considered
after review of treatment guidelines and careful clinical
assessment of individual patients.

Limitations

This was a single centre study and our patient population
was relatively small, raising the possibility of selection bias.
However, subjects were enrolled consecutively and followed
closely for a median period of almost 3 years. As in all observational studies, no conclusions can be drawn regarding
causality, even though the associations between diastolic
function, serum troponin and mortality were strong and independent of age, sex, and other factors adjusted for in the
multivariate model. Our study included a combination of
dialysis and non-dialysis patients and this may make the results more difficult to interpret, although we felt the inclusion and comparison of the two groups was valuable.
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Conclusion
Patients with advanced CKD have a high incidence of
structural cardiac abnormalities including increased LV
mass, diastolic dysfunction and raised troponin T. These
factors are associated with increased mortality and adverse cardiac events compared to CKD patients without
these factors, even in the non-dialysis population. We
therefore suggest routine evaluation of diastolic function
by echocardiography, measurement of serum troponin T
and screening for vascular risk factors in all CKD patients. Whether early identification of these risk markers
and intervention in CKD patients will lead to improved
outcomes should be the subject of further investigation.
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